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Introduction. Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults, is an aggressive malignancy
with a poor outcome. Current standard of care for newly diagnosed GBM includes trimodality treatment (Surgery, concomitant
Radiotherapy and Chemotherapy).
Objective. The aim of this study was to investigate if the demonstrated improved survival in the literature is translated to clinical
practice.
Materials and methods. This is a retrospective study between June 1996 and February 2013 that includes 163 patients with GBM.
Median age 62 years (24–87); 102 male (62.6%) and 61 female (37.4%); 63 patients (38.6%) received 2DCRT and 100 (61.4%) were
treated with 3DCRT. Performance status (PS-ECOG) 0=7.4% of the patients; 1 = 39.9%; 2=33.7%; 3=13.7%; 78 patients (47.9%)
had complete tumor resection, 59 (47.6%) incomplete resection and 18 (11%) received only biopsy; 147 patients (93%) received
chemotherapy, BCNU in 26 patients, Temozolamide (TMZ) concomitant in 12, TMZ concomitant and adjuvant 109. The Temporal
lobe (41.4%), right hemisphere (52.5%), unilobar localization (66.9%) were the most common sites affected. For survival analysis
patients were stratiﬁed by age, ECOG, and treatment modalities.
Results. The mean overall survival (mOSV) was 19.7 months (95% CI: 16.4–23.0); and mean progression-free survival (mPFSV) was
13.3 months (95% CI: 9.8–16.7) for the whole group. At 1 year mOSV was 54%, 2 years 25%, 3 years 13%, 4 years 10% and 6% at 5
years. The mPFSV at 1 year was 32%, 2 years 11%, 3 years 8%, 4 years 3% and 1% at 5 years. Factors identiﬁed as predictors of better
overall survival (OS) were: extent of resection (p=0.000 Log Rank); ECOG 0 vs. 1–3 (p=0.031 Long Rank) and type of chemotherapy
TMZ vs. BCNU (p=0.006 Log Rank). On the other hand: 3DCRT vs. 2DCRT (p=0.644 Long Rank), Sex (p=0.79 Long Rank), and age
of diagnosis (p=0.351 Long Rank), were not factors predictors of OS in our retrospective study.
Conclusions. Complete resections, TMZ associated with 3DCRT, ECOG 0 younger patients signiﬁcantly improve survival.
http://dx.doi.org/10.1016/j.rpor.2013.03.131
Glioblastoma multiforme: IMRT versus 3DCRT reirradiation in two patients
J. Morales Marco1, P. Soler Catalán1, F. Andreu Martínez1, R. Tortosa Oliver2, N. Chinillach Ferrando2
1 Hospital Imed Elche, Oncología Radioterápica, Spain
2 Hospital Imed Elche, Unidad de Radiofísica, Spain
Introduction. The reirradiation of a local relapse remains nowadays a challenge for the tumor control of patients diagnosed with
Glioblastoma Multiforme (GBM). It is not unusual that patients receive QT-RT after a surgical resection, with the underlying
effects, what makes even more difﬁcult to design the proper treatment for the patient, due to the previous treatments.
Objectives. To compare the different PTV coberture in the different planning techniques in two different patients: one treated
with 3DCRT versus another patient treated with IMRT.
Methods. Two patients diagnosed with a relapse of GBM, underwent Radiotherapy after a surgical resection of the tumor failure,
previously treated with QT-RT (Temozolamide plus 60Gy with 3DCRT) after surgical resection. Patient A: 24 year-old patient
received a total dose treatment of 37.5Gy, delivered in 15 sessions of 2.5Gy per fraction with 3DCRT. Patient B: 41 year-old patient
received a total dose treatment of 36Gy, delivered in 20 sessions of 1.8Gy per fraction with IMRT.
Results. Patient A: Radiation Technique: 3DCRT V95: 99.94%/V100: 78.82% D95: 36.7Gy/D100: 35.35Gy/Tronco: Dmáx: 5Gy, Dmedia:
1.16Gy Vías ópticas: Dmáx: 1.2Gy, Dmedia: 1Gy Patient 2: Radiation Technique: IMRT V95: 99.97%/V100: 91.05% D95: 35.65%/D100:
33.67%/Tronco: Dmáx: 35.07%, Dmedia: 19.91Gy Vías ópticas: Dmáx: 13.72Gy/Dmedia: 11.3 Gy.
Conclusions. We conclude that, although the planning comparison is between two different patients, the IMRT achieved a better
PTV coberture than 3DCRT with a good sparing of the OARs and eloquent areas.
http://dx.doi.org/10.1016/j.rpor.2013.03.132
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Introduction. Nowadays, patients diagnosed with Glioblastoma Multiforme (GBM) can be treated with different radiotherapy
techniques depending on the available technology of each radiation oncology department.
Objectives. To analyse the best treatment option with radiotherapy on a patient with several tumor control failures, previously
treated with surgery, surgery plus QT-RT and a new scheme of surgery plus QT-RT.
Methods. A 41-year-old patient diagnosed with GBM in 2003, who was operated with R0 without adjuvant treatment. Five years
later, the patient underwent a second surgery for a local relapse. Adjuvant treatment with QT-RT was delivered (Temozolamide
